

Technical Data

Mannitol Salt Agar Intended Use

Recommended for selective isolation of *Staphylococci* from pharmaceutical products in accordance with Microbial Limit Test by harmonized method of USP/EP/BP/JP/IP.

Composition**	
Ingredients	Gms / Litre
Peptone #	5.000
Tryptone ##	5.000
HM Peptone B ###	1.000
Sodium chloride	75.000
D-Mannitol	10.000
Phenol red	0.025
Agar	15.000
pH after sterilization (at 25°C)	7.4 ± 0.2
# Peptic digest of animal tissue	
## Pancreatic digest of casein	
### Equivalent to Beef extract	
**Formula adjusted, standardized to suit performance parameters	

Directions

Suspend 111.02 grams in 1000 ml purified/ distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes or as per validated cycle. Cool to 45-50°C. Mix well and pour into sterile Petru plates.

Note : This product contains 7.5% Sodium chloride as one of its ingredients. On repeated exposure to air and absorption moisture sodium chloride has tendency to form lumps, therefore we strongly recommend storage in tightly closed containers in dry place away from bright light.

Principle And Interpretation

Staphylococci are widespread in nature, although they are mainly found on the skin, skin glands and mucous membranes of mammals and birds. The coagulase-positive species i.e. *Staphylococcus aureus* is well documented as a human opportunistic pathogen. The ability to clot plasma continues to be the most widely used and accepted criterion for the identification of pathogenic *staphylococci* associated with acute infections (1). *Staphylococci* have the unique ability of growing on a high salt containing media (2). Isolation of coagulase-positive staphylococci on Phenol Red Mannitol Agar supplemented with 7.5%NaCl was studied by Chapman (3). The resulting Mannitol Salt Agar Base is recommended for the isolation of coagulase-positive staphylococci from cosmetics, milk, food and other specimens (1,4,5,6,7). The additional property of lipase activity of *Staphylococcus aureus* can be detected by the addition of the Egg Yolk Emulsion (FD045). The lipase activity can be visualized as yellow opaque zones around the colonies (8). It is also used in the performance of microbial limit tests for the selective isolation of *Staphylococcus*. The formulation is in accordance with the harmonization of USP/EP/BP/JP/IP (9,10,11,12,13).

The medium contains HM peptone B, tryptone and peptone which makes it very nutritious as they provide carbon, nitrogen compounds, long chain amino acids, vitamins and other essential growth factors and trace nutrients. Many other bacteria except *Staphylococci* are inhibited by 7.5% sodium chloride. Mannitol is the fermentable carbohydrate fermentation of which leads to acid production, detected by phenol red indicator.

S.aureus ferment mannitol and produce yellow coloured colonies surrounded by yellow zones. Coagulase-negative strains of *S.aureus* are usually mannitol non-fermenters and therefore produce pink to red colonies surrounded by red-purple zones. Presumptive coagulase-positive yellow colonies of *S.aureus* should be confirmed by performing the coagulase test [tube or slide (1)]. Lipase activity of *S.aureus* can be detected by supplementing the medium with egg yolk emulsion

MH118

A possible *S.aureus* must be confirmed by the coagulase test. Also the organism should be subcultured to a less inhibitory medium not containing excess salt to avoid the possible interference of salt with coagulase testing or other diagnostic tests (e.g. Nutrient Broth)(M002) (14). Few strains of *S.aureus* may exhibit delayed mannitol fermentation. Negative results should therefore be re-incubated for an additional 24 hours before being discarded (14).

Type of specimen

Pharmaceutical samples

Specimen Collection and Handling

For pharmaceutical samples, follow appropriate techniques for sample collection, processing as per guidelines (9,10,11,12,13).

After use, contaminated materials must be sterilized by autoclaving before discarding.

Warning and Precautions:

Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling specimens. Safety guidelines may be referred in individual safety data sheets.

Limitations

1. This medium is a selective medium, some strains of *Staphylococcus aureus* may exhibit a delayed fermentation of mannitol.

Performance and Evaluation

Performance of the medium is expected when used as per the direction on the label within the expiry period when stored at recommended temperature.

Quality Control

Appearance

Light yellow to pink homogeneous free flowing powder

Gelling

Firm, comparable with 1.5% Agar gel

Colour and Clarity of prepared medium

Red coloured clear to slightly opalescent gel forms in Petri plates

pН

7.20-7.60

Growth Promotion Test

Growth Promotion was carried out in accordance with the harmonized method of USP/EP/BPJP/IP, after an incubation at 30-35°C for 18-72 hours. Recovery rate is considered as 100% for bacteria growth on Soybean Casein Digest Agar.

Growth promoting properties

Growth of microorganism comparable to that previously obtained with previously tested and approved lot of medium occurs at the specified temperature for not more than the shortest period of time specified inoculating ≤ 100 cfu(at 30-35°C for ≤ 18 hours).

Indicative properties

Colonies are comparable in appearance and indication reaction to those previously obtained with previously tested and approved lot of medium occurs for the specified temperature for a period of time within the range specified inoculating ≤ 100 cfu (at 30-35°C for 18-72 hours).

Inhibitory properties

No growth of the test microorganism occurs for the specified temp for not less than longest period of time specified inoculating ≥ 100 cfu (at 30-35°C for ≥ 72 hours).

HiMedia Laboratories

Organism	Inoculum (CFU)	Growth	Observed Lot value (CFU)	Recovery	Colour of colony	Incubation temperature
Growth Promoting + Indicative						
Staphylococcus aureus subsp. aureus ATCC 6538 (00032*)	50 -100	luxuriant	25 -100	>=50 %	yellow/white colonies surrounded by yellow zone	18 -72 hrs
Inhibitory						
<i>Escherichia coli</i> ATCC 8739 (00012*)	>=10 ³	inhibited	0	0 %		>=72 hrs
Additional Microbiological	l					
testing						
Staphylococcus aureus subsp. aureus ATCC 25923 (00034*)	50 -100	luxuriant	25 -100	>=50 %	yellow/white colonies surrounded by yellow zone	18 -72 hrs
Staphylococcus epidermidis ATCC 12228 (00036*)	50 -100	fair - good	15 -40	30 -40 %	red	18 -72 hrs
Staphylococcus epidermidis ATCC 14990 (00132*)	50 -100	fair - good	15 -40	30 -40 %	red	18 -72 hrs
Proteus mirabilis ATCC 12453	50 -100	none-poor	0 -10	0 -10 %	yellow	18 -72 hrs
<i>Escherichia coli</i> ATCC 25922 (00013*)	>=10 ³	inhibited	0	0%		>=72 hrs
Escherichia coli NCTC 900	$2 >= 10^{3}$	inhibited	0	0%		>=72 hrs
# <i>Klebsiella aerogenes</i> ATCC 13048	>=10 ³	inhibited	0	0%		>=72 hrs

Key: (#) Formerly known as Enterobacter aerogenes, (*) Corresponding WDCM numbers

Storage and Shelf Life

Store between 10-30°C in a tightly closed container and the prepared medium at 20-30°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle in order to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition Seal the container tightly after use. Product performance is best if used within stated expiry period.

Disposal

User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with sample must be decontaminated and disposed of in accordance with current laboratory techniques (14,15).

Reference

- 1. Murray P. R., Baron J. H., Pfaller M. A., Jorgensen J. H. and Yolken R. H., (Ed.), 2003, Manual of Clinical Microbiology, 8th Ed., American Society for Microbiology, Washington, D.C.
- 2. Koch P. K., 1942, Zentralbl. Bakteriol. Parasitenkd. Abt. I Orig.149:122.
- 3. Chapman G. H., 1945, J. Bacteriol., 50:201.
- 4. American Public Health Association, 1966, Recommended Methods for the Microbiological Examination of Foods, 2nd Ed, APHA, New York.
- 5. Davis J. G., 1959, Milk testing, 2nd Ed., Dairy Industries Ltd, London.
- Hitchins A. D., Tran T. and McCarron J. E., 1995, FDA Bacteriological Analytical Manual, 8th Ed., AOAC International, Gaithersburg, Md.
- 7. Silverton R. E. and Anderson M. J., 1961, Handbook of Medical Laboratory Formulae, Butterworths, London.
- 8. Gunn B. A., Dunkelberg W. E. and Creitz J. R., 1972, Am. J. Clin. Pathol., 57:236.
- 9. The United States Pharmacopoeia-National Formulatory (USP-NF), 2022.
- 10. European Pharmacopoeia, 2022, 10 th volume, European Directorate for the quality of medicines & Healthcare.

HiMedia Laboratories Pvt. Ltd. Corporate Office : Plot No.C-40, Road No.21Y, MIDC, Wagle Industrial Area, Thane (W) - 400604, India. Customer care No.: 022-6147 1919 Email: techhelp@himedialabs.com Website: www.himedialabs.com

11. The British Pharmacopoeia, 2022, Medicines and Healthcare products Regulatory Agency.

12. The Japanese Pharmacopoeia, 17th edition, 2016, The Ministry of Health, Labour and welfare.

13.Indian Pharmacopoeia, 2022, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare Government of India.

14. Isenberg, H.D. Clinical Microbiology Procedures Handbook 2nd Edition.

15.Jorgensen, J.H., Pfaller, M.A., Carroll, K.C., Funke, G., Landry, M.L., Richter, S.S and Warnock., D.W. (2015) Manual of Clinical Microbiology, 11th Edition. Vol. 1.

Revision : 05/2023

Disclaimer :

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMediaTM publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMediaTM Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.